Cagrilintide

World Peptide Foundation

Where is Cagrilintide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Cagrilintide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Amylin analog

Cagrilintide is an amylin analog investigated for weight management, both alone and in combinations such as CagriSema. Evidence for the single agent must be separated from evidence for the combination.

Record status

Traceability partial

Last meaningful update: 9/26/2026

Evidence searched through:: Not recorded
Assessment updated:: 9/26/2026
Documented human review:: No documented human review recorded
Automated scientific assessment:: 9/26/2026
AI source check:: 9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

118

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observation Archive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

118

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

Independent evidence dossiers covering the major research questions.

Published source records

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

Conflicting evidence relationships that remain visible.

Research gaps

Questions the current record identifies as unresolved.

Connected media

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

12 published domain syntheses connected to 36 featured studies

Cagrilintide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas

Evidence boundary

Featured evidence

Domain links

See graph

Contradicting

With explicit limits

What this does not establish

• WPF’s existing atlas includes systematic reviews and network meta-analyses comparing cagrilintide, CagriSema, semaglutide, and other interventions. These syntheses pose different questions and may combine heterogeneous trials; a title or indirect comparison is not proof of relative superiority.
• No published source-linked citation or jurisdiction-specific regulatory record has been promoted into this Directory entry. Combined-treatment results cannot be attributed to cagrilintide alone, and follow-up duration and safety outcomes need separate appraisal.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.

Inspect the published evidence record41 governed records · titles, provenance, and original-source linksOpen records ↓

2026Phase 3 human evidence

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Content-verified record concerning Cagrilintide: "Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study." Abstract excerpt: The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight. We aimed to investigate the efficacy and safety of a fixed-dose combination of cagrilintide and semaglutide (cagrilintide-semaglutide; known as CagriSema) versus semaglutide or cagrilintide for glycaemic control in people with type 2 diabetes and overw

Source: peer_reviewed_research
DOI: 10.1016/s2213-8587(26)00125-7
PubMed: 42251859

Open original source

2026Phase 3 human evidence

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Content-verified record concerning Cagrilintide: "Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study." Abstract excerpt: Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia. We aimed to compare the efficacy and safety of a once per week combination of cagrilintide with semaglutide (CagriSema) versus placebo as an add-on to basal insulin in individuals with type 2 diabetes. This double-blind, parallel-group, r

Source: peer_reviewed_research
DOI: 10.1016/s0140-6736(26)01022-6
PubMed: 42251856

Open original source

2021Phase 1–2 human evidence

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Content-verified record concerning Cagrilintide: "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial." Abstract excerpt: Cagrilintide, a long-acting amylin analogue, and semaglutide 2·4 mg, a glucagon-like peptide-1 analogue, are both being investigated as options for weight management. We aimed to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of this drug combination. In this randomised, placebo-controlled, multiple-ascending dose, phase 1b trial, individuals aged 18-55 years with

Source: peer_reviewed_research
DOI: 10.1016/s0140-6736(21)00845-x
PubMed: 33894838

Open original source

2021Phase 1–2 human evidence

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Content-verified record concerning Cagrilintide: "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial." Abstract excerpt: Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We assessed the dose-response relationship of cagrilintide regarding the effects on bodyweight, safety, and tolerability. We conducted a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial at 57

Source: peer_reviewed_research
DOI: 10.1016/s0140-6736(21)01751-7
PubMed: 34798060

Open original source

2026Phase 1–2 human evidence

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Content-verified record concerning Cagrilintide: "Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." Abstract excerpt: Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. We aimed to assess the efficacy and safety of cagrilintide-semaglutide for people with type 2 diabetes inadequately controlled with diet and exercise. REIMAGINE 1 was a randomised, double-blind, parallel-group, phase 3a study carried out a

Source: peer_reviewed_research
DOI: 10.1016/s2213-8587(26)00126-9
PubMed: 42251860

Open original source

2026Phase 1–2 human evidence

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

Content-verified record concerning Cagrilintide: "Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial." Abstract excerpt: The combination of cagrilintide and semaglutide has been shown in global studies to induce reductions in bodyweight. We assessed the efficacy and safety of a fixed-dose combination of cagrilintide 2·4 mg and semaglutide 2·4 mg versus semaglutide 2·4 mg for weight management in an east Asian population. This double-blind, parallel-group, phase 3a trial (REDEFINE 5) was conducted acro

Source: peer_reviewed_research
DOI: 10.1016/s2213-8587(25)00402-4
PubMed: 42009015

Open original source

2023Phase 1–2 human evidence

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Content-verified record concerning Cagrilintide: "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial." Abstract excerpt: Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA 1c ) is unknown. This trial assessed the efficacy and safety of co-administered semaglutide with cagrilintide (CagriSema) in participants with type 2 diabetes. This 32-week, multicentre, double-blind, phase 2 trial was conducted across

Source: peer_reviewed_research
DOI: 10.1016/s0140-6736(23)01163-7
PubMed: 37364590

Open original source

2025Animal research

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

Directly concerns the combination in adults with overweight or obesity; does not isolate cagrilintide alone.

Source: peer_reviewed_research
DOI: 10.1056/NEJMoa2502081
PubMed: 40544433

Open original source

2025Animal research

In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.

Content-verified record concerning Cagrilintide: "In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk." Abstract excerpt: GIM/FP/GP: [Formula: see text].

Source: peer_reviewed_research
DOI: 10.7326/annals-25-03745-jc
PubMed: 41052437

Open original source

2026Animal research

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

Content-verified record concerning Cagrilintide: "Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats." Abstract excerpt: Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obe

Source: peer_reviewed_research
DOI: 10.1038/s42255-026-01603-y
PubMed: 42744908

Open original source

2026Animal research

A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.

Content-verified record concerning Cagrilintide: "A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance." Abstract excerpt: Amylin receptor agonists such as cagrilintide represent emerging obesity therapies. To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC). Here we show that cagrilintide regulate

Source: peer_reviewed_research
DOI: 10.1038/s42255-026-01539-3
PubMed: 42260119

Open original source

2025Animal research

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Content-verified record concerning Cagrilintide: "Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes." Abstract excerpt: Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring. In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12

Source: peer_reviewed_research
DOI: 10.1056/NEJMoa2502082
PubMed: 40544432

Open original source

2022Animal research

Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.

Content-verified record concerning Cagrilintide: "Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models." Abstract excerpt: Cagrilintide is a novel long-acting amylin receptor agonist, which has shown a potent induction of weight loss. Interestingly, cagrilintide is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) derived from an amylin backbone. Another class of long-acting DACRAs exists, namely the KBPs. These are salmon calcitonin-based and have shown preclinical potential; however, how and if they differentiat

Source: peer_reviewed_research
DOI: 10.1016/j.biopha.2022.113842
PubMed: 36242844

Open original source

2025Animal research

Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.

Content-verified record concerning Cagrilintide: "Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide." Abstract excerpt: Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for mouse and rat in vivo and in vitro studies of amylin analogues such as cagrilintide. Structurally, 0839 shares 95 % sequence homology with 0833 a

Source: peer_reviewed_research
DOI: 10.1016/j.lfs.2025.123845
PubMed: 40628316

Open original source

2024Laboratory research

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

Content-verified record concerning Cagrilintide: "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity." Abstract excerpt: Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the

Source: peer_reviewed_research
DOI: 10.1097/CRD.0000000000000513
PubMed: 36883831

Open original source

Insufficient evidence

A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1101/2025.01.13.632726

Open original source

Insufficient evidence

A combined cryo_EM structure of Cagrilintide-CTR-Gs complex

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.2210/pdb9uwm/pdb

Open original source

Insufficient evidence

A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.2210/pdb9uwq/pdb

Open original source

Insufficient evidence

1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.2337/db25-1969-lb

Open original source

2026Insufficient evidence

Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.

Content-verified record concerning Cagrilintide: "Cagrilintide-semaglutide: a new option for patients with type 2 diabetes." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1016/s2213-8587(26)00129-4
PubMed: 42251858

Open original source

2024Insufficient evidence

Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.

Content-verified record concerning Cagrilintide: "Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants." Abstract excerpt: The combination of cagrilintide and semaglutide (CagriSema) is being developed for the treatment of obesity and type 2 diabetes. The objective of this thorough QT study was to confirm that cagrilintide does not result in a clinically relevant prolongation in cardiac repolarization compared with placebo. This was a double-blind study (NCT05804162) in which healthy participants were randomized to ca

Source: peer_reviewed_research
DOI: 10.1111/dom.15951
PubMed: 39279639

Open original source

2026Insufficient evidence

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Content-verified record concerning Cagrilintide: "Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis." Abstract excerpt: Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of cagrilintide-based therapies in adults with overwe

Source: systematic_review_or_meta_analysis
DOI: 10.1007/s40200-026-01942-3
PubMed: 42180166

Open original source

2026Insufficient evidence

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Content-verified record concerning Cagrilintide: "Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression." Abstract excerpt: Obesity is a complex chronic disease requiring effective long-term management. We performed a systematic review and meta-analysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintid

Source: systematic_review_or_meta_analysis
DOI: 10.1111/dom.70667
PubMed: 41834765

Open original source

2024Insufficient evidence

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Content-verified record concerning Cagrilintide: "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Abstract excerpt: No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, l

Source: systematic_review_or_meta_analysis
DOI: 10.4103/ijem.ijem_45_24
PubMed: 39676787

Open original source

2026Insufficient evidence

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Content-verified record concerning Cagrilintide: "Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo." Abstract excerpt: Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches. This systematic review and meta-analysis evaluated their efficacy and safety in adults with overweight or obesity. Four databases were searched from i

Source: systematic_review_or_meta_analysis
DOI: 10.1097/ms9.0000000000005353
PubMed: 42583410

Open original source

2026Insufficient evidence

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

Content-verified record concerning Cagrilintide: "Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide." Abstract excerpt: Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes. Two studies were conducted to assess the effects of renal or hepatic impairment on pharmacokinetics, safety and tolerability following sin

Source: peer_reviewed_research
DOI: 10.1007/s40262-026-01654-0
PubMed: 42228334

Open original source

2021Insufficient evidence

Development of Cagrilintide, a Long-Acting Amylin Analogue.

Content-verified record concerning Cagrilintide: "Development of Cagrilintide, a Long-Acting Amylin Analogue." Abstract excerpt: A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acti

Source: peer_reviewed_research
DOI: 10.1021/acs.jmedchem.1c00565
PubMed: 34288673

Open original source

2025Insufficient evidence

Cagrilintide-Semaglutide in Adults with Overweight or Obesity.

Content-verified record concerning Cagrilintide: "Cagrilintide-Semaglutide in Adults with Overweight or Obesity." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1056/nejmc2513141
PubMed: 41259764

Open original source

2026Insufficient evidence

Cellular loci for cagrilintide action identified.

Content-verified record concerning Cagrilintide: "Cellular loci for cagrilintide action identified." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1038/s42255-026-01541-9
PubMed: 42260118

Open original source

2021Insufficient evidence

Cagrilintide plus semaglutide for obesity management.

Content-verified record concerning Cagrilintide: "Cagrilintide plus semaglutide for obesity management." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1016/s0140-6736(21)00944-2
PubMed: 33894837

Open original source

Insufficient evidence

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1002/edm2.70248
PubMed: 42207966

Open original source

Insufficient evidence

Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1111/dom.70667/v1/decision1

Open original source

Insufficient evidence

26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1016/j.jacc.2026.02.688

Open original source

Insufficient evidence

1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.2337/db26-1713-p

Open original source

Insufficient evidence

Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1038/s41401-025-01635-2
PubMed: 40847076

Open original source

Insufficient evidence

Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1111/dom.70667/v2/review1

Open original source

Insufficient evidence

26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1016/j.jacc.2026.02.652

Open original source

Insufficient evidence

Author response for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1111/dom.70667/v2/response1

Open original source

Insufficient evidence

Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1111/dom.70667/v2/decision1

Open original source

Insufficient evidence

2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.2337/db26-2458-p

Open original source

Insufficient evidence

Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Source reference associated with Cagrilintide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source: other
DOI: 10.1111/dom.70667/v1/review3

Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓

Chemical identity

Molecular and structural record

Structured record

Molecular formula: C194H312N54O59S2
Molecular weight (Da): 4409
InChI: InChI=1S/C194H312N54O59S2/c1-19-100(10)151(184(298)233-128(78-98(6)7)189(303)248-75-49-60-137(248)190(304)247-74-48-59-136(247)182(296)243-155(107(17)255)187(301)232-127(86-143(201)262)173(287)238-150(99(8)9)183(297)210-88-146(265)218-129(90-249)176(290)230-126(85-142(200)261)175(289)244-156(108(18)256)191(305)246-73-46-57-134(246)157(202)271)239-181(295)135-58-47-72-245(135)147(266)89-211-161(275)120(79-109-50-36-34-37-51-109)225-171(285)123(82-139(197)258)228-172(286)124(83-140(198)259)229-177(291)130(91-250)235-178(292)131(92-251)234-170(284)122(81-111-87-207-95-212-111)227-164(278)114(56-45-71-209-194(205)206)221-168(282)119(77-97(4)5)224-169(283)121(80-110-52-38-35-39-53-110)226-166(280)116(65-68-149(269)270)219-158(272)101(11)213-167(281)118(76-96(2)3)223-163(277)113(55-44-70-208-193(203)204)220-165(279)115(63-66-138(196)257)222-186(300)153(105(15)253)240-159(273)102(12)214-179(293)132-93-308-309-94-133(180(294)231-125(84-141(199)260)174(288)242-152(104(14)252)185(299)215-103(13)160(274)241-154(106(16)254)188(302)237-132)236-162(276)112(54-42-43-69-195)216-145(264)67-64-117(192(306)307)217-144(263)61-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-62-148(267)268/h34-39,50-53,87,95-108,112-137,150-156,249-256H,19-33,40-49,54-86,88-94,195H2,1-18H3,(H2,196,257)(H2,197,258)(H2,198,259)(H2,199,260)(H2,200,261)(H2,201,262)(H2,202,271)(H,207,212)(H,210,297)(H,211,275)(H,213,281)(H,214,293)(H,215,299)(H,216,264)(H,217,263)(H,218,265)(H,219,272)(H,220,279)(H,221,282)(H,222,300)(H,223,277)(H,224,283)(H,225,285)(H,226,280)(H,227,278)(H,228,286)(H,229,291)(H,230,290)(H,231,294)(H,232,301)(H,233,298)(H,234,284)(H,235,292)(H,236,276)(H,237,302)(H,238,287)(H,239,295)(H,240,273)(H,241,274)(H,242,288)(H,243,296)(H,244,289)(H,267,268)(H,269,270)(H,306,307)(H4,203,204,208)(H4,205,206,209)/t100-,101-,102-,103-,104+,105+,106+,107+,108+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123+,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,150-,151-,152-,153-,154-,155-,156-/m0/s1
InChIKey: LDERDVMBIYGIOI-DDPFBLHVSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2021 · study · Temporal status not established
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
peer_reviewed_research
2021 · study · Temporal status not established
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
peer_reviewed_research
2021 · study · Temporal status not established
Development of Cagrilintide, a Long-Acting Amylin Analogue.
peer_reviewed_research
2021 · study · Temporal status not established
Cagrilintide plus semaglutide for obesity management.
peer_reviewed_research
2022 · study · Temporal status not established
Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
peer_reviewed_research
2023 · study · Temporal status not established
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
peer_reviewed_research
2024 · study · Temporal status not established
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
peer_reviewed_research
2024 · study · Temporal status not established
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
peer_reviewed_research
2024 · study · Temporal status not established
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
systematic_review_or_meta_analysis
2025 · study · Temporal status not established
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
peer_reviewed_research
2025 · study · Temporal status not established
In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
peer_reviewed_research
2025 · study · Temporal status not established
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
peer_reviewed_research
2025 · study · Temporal status not established
Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.
peer_reviewed_research
2025 · study · Temporal status not established
Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
peer_reviewed_research
2026 · study · Temporal status not established
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
peer_reviewed_research
2026 · study · Temporal status not established
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
peer_reviewed_research
2026 · study · Temporal status not established
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
peer_reviewed_research
2026 · study · Temporal status not established
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
peer_reviewed_research
2026 · study · Temporal status not established
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
peer_reviewed_research
2026 · study · Temporal status not established
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
peer_reviewed_research
2026 · study · Temporal status not established
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
peer_reviewed_research
2026 · study · Temporal status not established
Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
peer_reviewed_research
2026 · study · Temporal status not established
Cellular loci for cagrilintide action identified.
peer_reviewed_research
2026 · regulatory · Temporal status not established
Regulatory review: not_approved
European Union — EMA
2026 · regulatory · Temporal status not established
Regulatory review: not_approved
United States — FDA
Date unavailable · study · Temporal status not established
A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance
other
Date unavailable · study · Temporal status not established
A combined cryo_EM structure of Cagrilintide-CTR-Gs complex
other
Date unavailable · study · Temporal status not established
A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex
other
Date unavailable · study · Temporal status not established
1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity
other
Date unavailable · study · Temporal status not established
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
other
Date unavailable · study · Temporal status not established
Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
other
Date unavailable · study · Temporal status not established
26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS
other
Date unavailable · study · Temporal status not established
1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys
other
Date unavailable · study · Temporal status not established
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
other
Date unavailable · study · Temporal status not established
Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
other
Date unavailable · study · Temporal status not established
26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS
other
Date unavailable · study · Temporal status not established
Author response for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
other
Date unavailable · study · Temporal status not established
Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
other
Date unavailable · study · Temporal status not established
2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice
other
Date unavailable · study · Temporal status not established
Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"
other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 3 represented connections ↓

institution

peer_reviewed_research

represented evidence source

institution

other

represented evidence source

institution

systematic_review_or_meta_analysis

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 12 domain conclusions and 36 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Cagrilintide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

European Union — EMA

Regulator: EMA

not_approved

As of: 9/23/2026 · Temporal status not established

European Medicines Agency medicines database

United States — FDA

Regulator: FDA

not_approved

As of: 9/23/2026 · Temporal status not established

FDA Drugs@FDA database

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.

Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.

Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.

Contradictory and qualifying evidence must remain visible rather than being silently discarded.

Absence of represented evidence is not evidence that research does not exist.

Research gaps identify unresolved questions; they are not negative conclusions.

Regulatory status is distinct from scientific evidence quality.

Media relationships provide context and explanation; they do not increase the strength of scientific evidence.

A section with no represented records is an incomplete project record, not a scientific conclusion.

Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:48 PM

global evidence atlas

Cagrilintide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

Investigational boundary: Cagrilintide is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.

118Discoverable source universe

118Ranked screening records

12Research domains

2Governed published sources

SearchDomainEvidence class

118 matching records · ranked 2026-09-18

Page 1 of 5

#1Proposed tier Ameta analysisAwaiting human appraisal

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

BMJ medicine · 2026 · PMID 42688617 · DOI 10.1136/bmjmed-2026-003026

Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness

#2Proposed tier Ameta analysisAwaiting human appraisal

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.

The American journal of cardiology · 2026 May 15 · PMID 41759565 · DOI 10.1016/j.amjcard.2026.02.030

Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Comparative effectiveness

#3Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Diabetes, obesity & metabolism · 2026 Jun · PMID 41834765 · DOI 10.1111/dom.70667

Weight loss and obesity · CagriSema combination evidence · Safety and tolerability · Comparative effectiveness

#4Proposed tier Ameta analysisAwaiting human appraisal

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.

Endocrinology, diabetes & metabolism · 2026 May · PMID 42175595 · DOI 10.1002/edm2.70247

Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Comparative effectiveness

#5Proposed tier Ameta analysisAwaiting human appraisal

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Annals of medicine and surgery (2012) · 2026 Aug · PMID 42583410 · DOI 10.1097/MS9.0000000000005353

Weight loss and obesity · Amylin biology · CagriSema combination evidence · Comparative effectiveness

#6Proposed tier Ameta analysisAwaiting human appraisal

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Journal of diabetes and metabolic disorders · 2026 Jun · PMID 42180166 · DOI 10.1007/s40200-026-01942-3

Weight loss and obesity · CagriSema combination evidence · Safety and tolerability

#7Proposed tier Ameta analysisAwaiting human appraisal

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

Endocrinology, diabetes & metabolism · 2026 Jul · PMID 42207966 · DOI 10.1002/edm2.70248

Weight loss and obesity · CagriSema combination evidence · Comparative effectiveness

#8Proposed tier Ameta analysisAwaiting human appraisal

Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

Annals of internal medicine · 2026 Aug · PMID 42296503 · DOI 10.7326/ANNALS-24-03764

Weight loss and obesity · Mechanism and pharmacology · Comparative effectiveness

#9Proposed tier Ameta analysisAwaiting human appraisal

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

BMJ (Clinical research ed.) · 2024 Jan 29 · PMID 38286487 · DOI 10.1136/bmj-2023-076410

Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Mechanism and pharmacology · Comparative effectiveness

#10Proposed tier Ameta analysisAwaiting human appraisal

Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.

Obesity (Silver Spring, Md.) · 2026 Sep · PMID 41189318 · DOI 10.1002/oby.70054

Weight loss and obesity · Safety and tolerability

#11Proposed tier Ameta analysisAwaiting human appraisal

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

BMJ (Clinical research ed.) · 2026 Jul 8 · PMID 42419792 · DOI 10.1136/bmj-2026-372161

Weight loss and obesity · Comparative effectiveness

#12Proposed tier Ameta analysisAwaiting human appraisal

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.

Naunyn-Schmiedeberg's archives of pharmacology · 2026 Aug 17 · PMID 42608559 · DOI 10.1007/s00210-026-05809-5

Weight loss and obesity · CagriSema combination evidence

#13Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Indian journal of endocrinology and metabolism · 2024 Sep-Oct · PMID 39676787 · DOI 10.4103/ijem.ijem_45_24

Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Safety and tolerability

#14Proposed tier Asystematic reviewAwaiting human appraisal

Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.

Annals of internal medicine · 2026 Sep 1 · PMID 42673585 · DOI 10.7326/ANNALS-25-05519

Weight loss and obesity · Amylin biology · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology

#15Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024 Feb · PMID 38242040 · DOI 10.1016/j.biopha.2024.116150

Weight loss and obesity · Safety and tolerability · Comparative effectiveness

#16Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

The lancet. Diabetes & endocrinology · 2026 Jun · PMID 42009015 · DOI 10.1016/S2213-8587(25)00402-4

Weight loss and obesity · CagriSema combination evidence · Monotherapy evidence · Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness · Ongoing development

#17Proposed tier Ameta analysisAwaiting human appraisal

Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.

BMJ open · 2025 Sep 21 · PMID 40976663 · DOI 10.1136/bmjopen-2025-103668

Ongoing development

#18Proposed tier Arandomized trialAwaiting human appraisal

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

The lancet. Diabetes & endocrinology · 2026 Aug · PMID 42251859 · DOI 10.1016/S2213-8587(26)00125-7

CagriSema combination evidence · Type 2 diabetes and glycemia · Comparative effectiveness · Ongoing development

#19Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

The lancet. Diabetes & endocrinology · 2026 Aug · PMID 42251860 · DOI 10.1016/S2213-8587(26)00126-9

CagriSema combination evidence · Type 2 diabetes and glycemia · Safety and tolerability · Ongoing development

#20Proposed tier Arandomized trialAwaiting human appraisal

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Lancet (London, England) · 2026 Jul 4 · PMID 42251856 · DOI 10.1016/S0140-6736(26)01022-6

CagriSema combination evidence · Type 2 diabetes and glycemia · Ongoing development

#21Proposed tier Asystematic reviewAwaiting human appraisal

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.

Cureus · 2025 Mar · PMID 40206909 · DOI 10.7759/cureus.80321

Weight loss and obesity · CagriSema combination evidence

#22Proposed tier Arandomized trialAwaiting human appraisal

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Hypertension (Dallas, Tex. : 1979) · 2026 Feb · PMID 41328546 · DOI 10.1161/HYPERTENSIONAHA.125.26055

Weight loss and obesity · CagriSema combination evidence

#23Proposed tier Arandomized trialAwaiting human appraisal

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

Clinical pharmacokinetics · 2026 Jul · PMID 42228334 · DOI 10.1007/s40262-026-01654-0

Safety and tolerability · Mechanism and pharmacology

#24Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

The lancet. Gastroenterology & hepatology · 2026 Sep · PMID 42456707 · DOI 10.1016/S2468-1253(26)00123-8

CagriSema combination evidence · Safety and tolerability

#25Proposed tier Arandomized trialAwaiting human appraisal

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.

Expert opinion on investigational drugs · 2025 Mar · PMID 40022548 · DOI 10.1080/13543784.2025.2472408

Weight loss and obesity · Amylin biology · Mechanism and pharmacology

Count reconciliation: 118 discoverable source records match the peptide identity query; 118 are retained in this bounded, ranked screening view; 2 belong to the separate governed layer labeled “Governed published sources.” Domain totals overlap because one publication may inform several questions.

Cagrilintide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

APA
World Peptide Foundation. (n.d.). Cagrilintide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 26, 2026.) https://www.worldpeptidefoundation.org/directory/cagrilintide
AMA / Vancouver
World Peptide Foundation. Cagrilintide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 26, 2026. https://www.worldpeptidefoundation.org/directory/cagrilintide

Where is Cagrilintide being studied?

Cagrilintide

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

12 published domain syntheses connected to 36 featured studies

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.

Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide’s Effects on Energy Balance

A combined cryo_EM structure of Cagrilintide-CTR-Gs complex

A combined Cryo_EM structure of Cagrilintide-AMY1R-Gs complex

1969-LB: Effect of Combined Therapy with Once-Weekly Subcutaneous Cagrilintide 2.4 mg and Semaglutide 2.4 mg (CagriSema) on Energy Intake, Gastric Emptying, and Appetite in Adults with Overweight or Obesity

Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.

Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

Development of Cagrilintide, a Long-Acting Amylin Analogue.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity.

Cellular loci for cagrilintide action identified.

Cagrilintide plus semaglutide for obesity management.

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.

Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

26-A-15734-ACC CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS

1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys

Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.

Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

26-A-9711-ACC CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS

Author response for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Decision letter for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

2458-P: Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice

Review for "Efficacy and Safety of Cagrilintide and Cagrisema versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression"

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

Development of Cagrilintide, a Long-Acting Amylin Analogue.

Cagrilintide plus semaglutide for obesity management.

Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.

Cagrilintide-Semaglutide in Adults with Overweight or Obesity.

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.

Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.

Cellular loci for cagrilintide action identified.

Regulatory review: not_approved